fluoromisonidazole has been researched along with gadolinium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamsen, TC; Chakraborty, G; Harpold, HL; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR; Wang, CH | 1 |
| Alvord, EC; Chakraborty, G; Hadley, J; Krohn, KA; Muzi, M; Rockne, R; Spence, AM; Swanson, KR; Szeto, MD | 1 |
2 other study(ies) available for fluoromisonidazole and gadolinium
| Article | Year |
|---|---|
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
Topics: Adult; Aged; Female; Gadolinium; Glioblastoma; Humans; Hypoxia; Magnetic Resonance Imaging; Male; Middle Aged; Misonidazole; Neovascularization, Pathologic; Positron-Emission Tomography; Prognosis; Survival Analysis; Tumor Burden | 2009 |
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
Topics: Adult; Brain Neoplasms; Cell Division; Computer Simulation; Contrast Media; Female; Fluorine Radioisotopes; Gadolinium; Glioblastoma; Humans; Image Enhancement; Magnetic Resonance Imaging; Middle Aged; Misonidazole; Neoplasm Invasiveness; Positron-Emission Tomography | 2009 |